Brief: Akoya Biosciences Q3 Gross Margin 62.3%
14/11/2024 21:00
Nov 14 (Reuters) - Akoya Biosciences Q3 revenue USD 18.8 million vs. IBES estimate USD 25.4 million. * outlook FY revenue USD 80-85 million
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks